GCP
FLNA

GSA Capital Partners’s Filana Therapeutics FLNA Stock Holding History

GSA Capital Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
269,410
+51,566
+24% +$73.5K 0.02% 1261
2026
Q1 		$368K Sell
217,844
-70,035
-24% -$144K 0.02% 1115
2025
Q4 		$570K Buy
+287,879
New +$922K 0.05% 723
2024
Q3 		– Sell
-24,753
Closed -$306K – 1965
2024
Q2 		$306K Buy
+24,753
New +$522K 0.02% 1274
2024
Q1 		– Sell
-23,819
Closed -$536K – 1928
2023
Q4 		$536K Buy
+23,819
New +$503K 0.05% 750
2021
Q3 		– Sell
-5,104
Closed -$436K – 1728
2021
Q2 		$436K Buy
+5,104
New +$273K 0.05% 720
2021
Q1 		– Sell
-18,646
Closed -$127K – 1443
2020
Q4 		$127K Buy
+18,646
New +$166K 0.02% 1071
2015
Q2 		– Sell
-15,965
Closed -$211K – 2160
2015
Q1 		$211K Sell
15,965
-11,150
-41% -$150K 0.01% 1905
2014
Q4 		$385K Sell
27,115
-1,943
-7% -$33.6K 0.03% 1111
2014
Q3 		$795K Buy
29,058
+17,145
+144% +$521K 0.04% 634
2014
Q2 		$480K Buy
+11,913
New +$441K 0.02% 1170

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

GSA Capital Partners's FLNA Position: Q2 2026 in Review

GSA Capital Partners increased its Filana Therapeutics (FLNA) stake by 24% in Q2 2026, buying an estimated $73.5K and bringing the position to 269,410 shares worth $321K. The position accounts for 0.02% of the portfolio, ranked #1261.

GSA Capital Partners first reported a position in FLNA in Q2 2014 and has held it in 11 quarters since. The position peaked at $795K in Q3 2014. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • GSA Capital Partners held 269,410 shares of Filana Therapeutics worth $321K as of Q2 2026.
  • GSA Capital Partners bought 51,566 Filana Therapeutics shares in Q2 2026, an estimated $73.5K.
  • Filana Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1261 holding.
  • GSA Capital Partners first reported a position in Filana Therapeutics in Q2 2014 and has held it in 11 quarters since.
  • GSA Capital Partners's Filana Therapeutics position peaked at $795K in Q3 2014.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.